Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer
NCT03657043Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Mar 2019
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of tisotumab vedotin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Seagen Inc. Primary endpoints: Number of Participants With Dose-Limiting Toxicities up to 28 days and Confirmed Objective Response Rate up to 9.7 months. Started Mar 2019; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03657043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657043.